Beam Therapeutics
BEAM
206 hedge funds and large institutions have $1.85B invested in Beam Therapeutics in 2023 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 76 increasing their positions, 58 reducing their positions, and 29 closing their positions.
31% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 58
4.34% more ownership
Funds ownership: 79.05% → 83.39% (+4.3%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 29
0% less funds holding
Funds holding: 207 → 206 (-1)
15% less capital invested
Capital invested by funds: $2.18B → $1.85B (-$330M)
34% less call options, than puts
Call options by funds: $13.2M | Put options by funds: $20.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Temasek Holdings
Singapore
|
+$48M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$44.3M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$15M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$14.2M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$10.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$14.2M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$6.25M |
| 3 |
Renaissance Technologies
New York
|
-$5.16M |
| 4 |
CAI
Capital Advisors Inc
Tulsa,
Oklahoma
|
-$4.24M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$4.09M |
BEAM Hedge Fund Activity: Q1 2023 in Review
206 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q1 2023, worth a combined $1.85B — down 15% from $2.18B a quarter earlier.
Fund positioning in BEAM was balanced in Q1 2023: 29 funds opened new positions, 29 closed out, 76 added to existing stakes and 58 trimmed.
The largest buyer was Temasek Holdings, adding an estimated $48M. The largest seller was Goldman Sachs, cutting an estimated $14.2M.
- 206 institutional investors held Beam Therapeutics (BEAM) as of Q1 2023, down from 207 in Q4 2022.
- Funds reported $1.85B of Beam Therapeutics stock for Q1 2023, down 15% quarter-over-quarter.
- 29 funds opened new Beam Therapeutics positions in Q1 2023 and 29 closed out, a net change of 0 holders.
- The largest Beam Therapeutics buyer in Q1 2023 was Temasek Holdings, an estimated $48M added.
- The largest Beam Therapeutics seller in Q1 2023 was Goldman Sachs, an estimated $14.2M sold.
Based on aggregated 13F filings for Q1 2023.